查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1994174

塑形市場：2026-2032年全球市場預測（依治療方法、技術、最終用戶和應用領域分類）

Body Contouring Market by Procedure Type, Technology, End User, Application Area - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，塑形市場價值將達到 4.3635 億美元，到 2026 年將成長至 4.9528 億美元，到 2032 年將達到 9.8314 億美元，複合年成長率為 12.30%。

主要市場統計數據
基準年 2025 4.3635億美元
預計年份：2026年 4.9528億美元
預測年份 2032 9.8314億美元
複合年成長率 (%) 12.30%

簡明扼要地介紹了不斷發展的體型雕塑生態系統，重點關注影響策略選擇、患者偏好和臨床實踐變化的各種技術的融合。

體型雕塑療法處於一個獨特的領域，它融合了三個領域：美容醫學、醫療設備工程和消費者健康需求。本文概述了當前的行業趨勢，重點關注技術創新、不斷變化的患者期​​望以及臨床通訊協定的成熟。該領域最初以外科手術為主，如今已發展成為涵蓋多種侵入性、微創和非侵入性手術的多元化頻譜，每種手術在療效、恢復時間和風險方面都各有優劣。因此，從醫療設備製造商和臨床醫生到經銷商和保險公司，相關人員必須應對前所未有的複雜決策環境。

能量型醫療設備的進步、患者的期望以及臨床技能的整合如何同時重塑治療路徑、競爭和商業化。

塑形領域正經歷一場變革，其驅動力主要來自三大趨勢：技術進步、消費者行為轉變以及不同醫療機構臨床技能的提升。技術進步體現在能量型治療方式的逐步模組化，從而提高了精準度並縮短了恢復時間。因此，非侵入性和微創療法正成為更多患者的可行選擇，逐漸打破了以往「手術優先」的思維模式。

本研究檢驗了2025 年關稅調整對整個塑形生態系統的供應鏈、籌資策略和定價趨勢的多方面影響。

2025年的關稅調整將對塑形產業產生多方面的影響，改變供應商的經濟狀況、定價策略和區域供應鏈。某些進口零件和成品關稅的提高將增加依賴跨境供應關係的製造商的收貨成本，最終擠壓利潤空間，並促使企業將生產轉移到近岸地區，同時實現採購合作夥伴的多元化。對於臨床營運商和經銷商，這些成本調整將迫使他們重新評估定價模式、設備升級的資本投資計畫以及庫存策略，以減輕價格波動的衝擊。

綜合細分分析揭示了治療類型、技術、最終用戶、應用領域和分銷管道如何相互作用，從而決定採用路徑和商業化槓桿作用。

透過觀點治療類型、技術、最終用戶、應用領域和分銷管道，細分市場層面的洞察揭示了不同的市場准入途徑、臨床工作流程和商業化策略。治療類型區分了三種不同的臨床和商業性路徑。侵入性治療在切除大面積組織和確保治療效果方面仍然具有優勢，但同時也意味著更長的恢復期和更高的資源消耗。另一方面，微創技術對於尋求顯著改善且希望最大限度減少恢復時間的患者來說，是一種相當吸引人的中間選擇。非侵入性治療持續獲得注重便利性和低風險的消費者的青睞。了解哪些治療類型與醫療服務提供者的服務模式相契合，對於醫療設備產品組合的定位和培訓投資至關重要。

市場結構和文化因素的區域差異如何導致世界各地商業化重點、法規要求和機會概況的差異？

區域趨勢塑造了獨特的競爭環境、法律規範和患者需求特徵，因此需要量身定製商業性和臨床策略來應對。在美洲，消費者對非侵入性和微創治療的接受度顯著更高，這得益於當地廣泛的審美文化、較高的可支配收入以及密集的美容診所和醫療水療中心網路，這些都促進了新型醫療設備技術的快速普及。相較之下，不同地區的監管環境和與保險公司的關係各不相同，因此，針對不同地區制定策略對於證明臨床療效和調整保險報銷至關重要。

在塑形產業，技術模組化、臨床檢驗和卓越的服務是至關重要的競爭要求，也是決定性的差異化因素。

主要企業之間的競爭格局圍繞著三大策略重點：技術差異化、臨床證據的建構以及能夠降低臨床應用門檻的端到端服務模式。市場領導正投資於模組化升級、多功能治療應用器以及能夠實現整合分析功能的平台技術，以展示治療效果並支援臨床醫生的決策。中型創新者傾向於專注於細分應用和成本績效優勢，而新興參與企業則致力於突破性的人體工學設計和訂閱式服務模式，以加速市場進入。

一項旨在協調產品組合、臨床證據、供應鏈韌性和通路最佳化，以加速產品推廣和成長的實用策略舉措。

產業領導者應採取一系列切實可行的舉措，將洞察轉化為市場優勢和業務永續營運。優先考慮產品組合策略，該戰略應平衡旗艦級多適應症施用器與針對特定解剖區域量身定做的靶向應用器和通訊協定，以滿足臨床醫生和患者的需求。同時，應投資嚴謹的臨床研究和真實世界數據收集，以支持相關聲明，將其納入培訓課程，並在適用情況下加快與支付方的合作。

嚴謹的混合方法研究途徑，結合對臨床醫生的訪談、醫療設備相關人員的意見以及全面的二手研究，檢驗了實用的行業見解。

本調查方法結合了與關鍵相關人員的對話和結構化的二次分析，以確保研究結果立足於當代實踐，並檢驗多方面證據的驗證。關鍵對話包括對美容診所、皮膚科診所、醫院和醫療保險機構的臨床醫生進行深度訪談，以了解他們選擇治療方法的原因、流程、培訓需求以及對術後支持的期望。這些定性見解與對製造商和分銷商的訪談結果進行交叉比對，以深入了解產品藍圖、服務模式和通路經濟效益。

結論闡述了產品開發、臨床檢驗和適應性商業化如何整合才能決定塑形市場的持續成功。

最後，塑形領域正處於一個轉折點，技術、消費者期望和臨床實踐在此交匯融合，為以患者為中心的護理和商業性創新開闢了新道路。有創、微創和非侵入性干預措施之間的平衡將繼續影響醫療服務提供者提供的服務，而每種療法的獨特優勢和互補治療方法的結合將帶來差異化的臨床價值。能夠將卓越的設備性能與可靠的臨床檢驗、全面的培訓和穩健的供應鏈模式相結合的製造商和分銷商，將能夠在多元化的市場中建立強大的影響力。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：依治療方法分類的塑形市場

  • 侵入性
  • 微創
  • 非侵入性

第9章：塑形市場：依技術分類

  • 冷凍溶脂
  • 高強度聚焦超音波
  • 雷射
    • 二極體
    • Nd：YAG
  • 高頻
    • 雙極
    • 單極

第10章：塑身市場：依最終用戶分類

  • 美容診所
  • 皮膚科診所
  • 醫院
  • 醫療水療中心

第11章 塑形市場：依應用領域分類

  • 腹部
  • 手臂
  • 後退
  • 大腿

第12章 塑身市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 塑形市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 塑身市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國塑形市場

第16章：中國塑形市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • AbbVie Inc.
  • Alma Lasers Ltd.
  • Asclepion Laser Technologies GmbH
  • Bausch Health Companies Inc.
  • BioPhotas, Inc
  • BTL Industries, Inc.
  • Candela Corporation
  • Cartessa Aesthetics
  • Cutera, Inc.
  • Cynosure LLC
  • DEKA MELA srl
  • ENDYMED Medical
  • Erchonia Corporation
  • Fotona DOO
  • InMode Ltd.
  • Lumenis Be Ltd.
  • Merz Pharma GmbH & Co. KGaA
  • MicroAire Surgical Instruments, LLC
  • Nouvag AG
  • Sciton Inc.
  • Sofwave Ltd.
  • Venus Concept Inc.
  • Zimmer MedizinSystems
Product Code: MRR-1A1A064C0455

The Body Contouring Market was valued at USD 436.35 million in 2025 and is projected to grow to USD 495.28 million in 2026, with a CAGR of 12.30%, reaching USD 983.14 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 436.35 million
Estimated Year [2026] USD 495.28 million
Forecast Year [2032] USD 983.14 million
CAGR (%) 12.30%

A concise primer on the evolving body contouring ecosystem highlighting technology convergence patient preferences and clinical practice shifts that shape strategic choices

Body contouring occupies a unique intersection between aesthetic medicine, medical device engineering, and consumer wellness demand. This introduction frames the contemporary landscape by emphasizing the convergence of technological innovation, shifting patient expectations, and the maturation of clinical protocols. Historically grounded in surgical solutions, the field has diversified into a spectrum of invasive, minimally invasive, and non-invasive procedures, each defined by trade-offs among efficacy, recovery time, and risk profile. As a result, stakeholders ranging from device manufacturers and clinical operators to distributors and payers must navigate a more complex decision matrix than ever before.

The introduction further explains how patient demographics and lifestyle trends contribute to demand heterogeneity. Increasing consumer emphasis on minimally disruptive interventions and faster recovery has prompted clinics and medispas to expand offerings, while hospitals and dermatology practices preserve higher-acuity procedures. Concurrently, regulatory scrutiny and reimbursement considerations continue to shape technology adoption pathways and commercial models. This section sets the stage for deeper analysis by clarifying the core drivers and constraints that define strategic choices for product development, clinical protocols, and go-to-market plans.

How simultaneous advances in energy-based devices patient expectations and clinical skill integration are reshaping treatment pathways competitive dynamics and commercialization

The body contouring landscape is undergoing transformative shifts driven by three simultaneous currents: technological refinement, consumer behavior change, and an expanded clinical skill set across provider types. Technological refinement includes the progressive modularization of energy-based modalities, which has improved precision while reducing downtime. As a result, non-invasive and minimally invasive interventions have become viable options for a broader patient cohort, altering the previously dominant surgical-first mindset.

Consumer behavior change manifests through heightened expectations for safety, speed, and measurable outcomes, which has elevated the importance of validated clinical data and patient-reported outcomes in purchasing decisions. Clinics and medispas that emphasize transparent treatment protocols and demonstrable results gain competitive advantage. At the same time, clinicians in dermatology clinics and hospitals are integrating multimodal approaches that combine technologies to optimize outcomes, spurring a trend toward bundled offerings and hybrid treatment pathways.

These shifts also influence commercialization: manufacturers now prioritize ergonomic device design, treatment personalization, and service models that support training and clinical adoption. The cumulative effect is a more fluid, outcome-driven market where differentiation arises from clinical evidence, operational simplicity, and the ability to deliver consistent results across diverse patient segments.

Examining the multifaceted consequences of 2025 tariff adjustments on supply chains procurement strategies and pricing dynamics across the body contouring ecosystem

Tariff changes in 2025 exert a multifaceted influence on the body contouring industry by altering supplier economics, pricing strategies, and regional supply chains. Increased duties on certain imported components and finished devices raise landed costs for manufacturers that rely on cross-border supply relationships, which in turn pressures margins and encourages nearshoring or diversification of procurement partners. For clinical operators and distributors, these cost adjustments necessitate a re-evaluation of pricing models, capital expenditure plans for equipment upgrades, and inventory strategies to mitigate sudden price volatility.

Beyond immediate cost impacts, tariffs catalyze strategic reconfiguration. Firms with flexible manufacturing footprints accelerate investments in local assembly and certified regional partners to preserve service levels and reduce exposure to trade policy shifts. Meanwhile, procurement teams weigh the total cost of ownership more heavily, factoring in lead times, spare-parts availability, and regulatory compliance across jurisdictions. The net effect is a more deliberate approach to vendor selection, where supply resilience and service quality gain prominence alongside device performance.

Clinics, hospitals, and medispas also respond operationally: some delay non-essential capital outlays to maintain cash flow, while others re-assess bundled service pricing to offset increased equipment costs. In short, the 2025 tariff environment acts as a catalyst for supply chain reorientation, procurement sophistication, and closer alignment between manufacturers and regional partners to safeguard continuity of care and commercial momentum.

Integrated segmentation analysis revealing how procedure types technologies end users application areas and distribution channels collectively determine adoption pathways and commercialization levers

Segment-level insights reveal differentiated adoption pathways, clinical workflows, and commercialization strategies when analyzed through the lenses of procedure type, technology, end user, application area, and distribution channel. Procedure type delineates three distinct clinical and commercial routes: invasive approaches retain strength for high-volume tissue resection and definitive outcomes but carry longer recovery and higher resource intensity; minimally invasive techniques provide a middle ground that appeals to patients seeking meaningful change with reduced downtime; non-invasive treatments continue to expand appeal among consumers prioritizing convenience and lower perceived risk. Understanding which procedure types align with a provider's service model is essential for positioning device portfolios and training investments.

Technology segmentation emphasizes modality-specific dynamics. Cryolipolysis maintains strong recognition for adipocyte-targeted applications, while high intensity focused ultrasound is favored where depth-selective fat reduction and skin tightening interplay. Laser technologies, including diode and Nd:YAG variants, show differentiated utility based on target tissue characteristics and clinician preference, and radiofrequency platforms-both bipolar and monopolar-are valued for dermal remodeling and collagen induction. Device selection therefore hinges on intended application areas and complementary treatment combinations.

End-user segmentation highlights that aesthetic clinics and medispas prioritize patient throughput, shorter procedure durations, and lower device complexity, whereas dermatology clinics and hospitals place higher emphasis on clinical evidence, multi-indication versatility, and integration with existing surgical workflows. Application area segmentation underscores anatomical considerations: abdomen and thigh treatments often demand higher energy delivery and deeper penetration, while arm and back applications require tailored ergonomics and smaller applicators. Distribution channel segmentation differentiates direct sales relationships that favor service-intensive, high-touch engagements from online sales pathways that support lower-cost, self-directed procurement; within online channels, digital marketplaces and manufacturer websites play distinct roles in discovery, purchase, and after-sales support. These segmentation dimensions collectively inform product roadmaps, clinical training programs, and channel strategies that align with provider needs and patient expectations.

How distinct regional market structures and cultural dynamics create divergent commercialization priorities regulatory requirements and opportunity profiles across global territories

Regional dynamics create distinct competitive environments, regulatory frameworks, and patient demand profiles that require tailored commercial and clinical approaches. The Americas demonstrate pronounced consumer receptivity to non-invasive and minimally invasive treatments driven by strong aesthetic culture, high disposable income segments, and a dense network of aesthetic clinics and medispas that favor rapid adoption of new device technologies. In contrast, the region's regulatory landscape and payer interactions vary by jurisdiction, which necessitates localized strategies for clinical validation and reimbursement alignment.

Europe, Middle East & Africa encompasses a heterogeneous set of markets where regulatory harmonization, reimbursement norms, and cultural attitudes toward aesthetic procedures differ markedly. Western European markets often emphasize clinical evidence and device certification, leading manufacturers to invest in rigorous studies and clinician training. Emerging markets within the region show strong growth potential driven by aspirational demand and expanding clinic networks, but they require adaptable pricing and distribution models to address affordability and infrastructure constraints.

Asia-Pacific presents a dynamic mix of sophisticated urban centers and rapidly developing markets. Urban populations in several countries display high demand for minimally invasive, quick-recovery treatments, supported by advanced clinical ecosystems and strong medical tourism flows. Elsewhere in the region, growth is underpinned by rising middle-class incomes, increasing acceptance of aesthetic procedures, and expanding access to specialized providers. Across all regions, manufacturers and distributors benefit from region-specific go-to-market strategies that reflect local clinical preferences, regulatory realities, and channel structure.

Competitive imperatives emphasizing technological modularity clinical validation and service excellence as decisive differentiators in the body contouring industry

Competitive dynamics among leading companies center on three strategic priorities: technological differentiation, clinical evidence generation, and end-to-end service models that reduce friction for clinical adoption. Market leaders invest in platform technologies that enable modular upgrades, versatile treatment applicators, and integrated analytics to demonstrate outcomes and support clinician decision-making. Mid-tier innovators tend to focus on niche applications or price-performance advantages, while emerging entrants pursue disruptive ergonomics or subscription-based service models to accelerate market access.

Partnerships between device manufacturers and clinical training organizations, as well as strategic distribution alliances, are increasingly central to capturing share in a complex market. Companies that provide robust training, warranty and maintenance programs, and data-driven marketing support help clinics shorten learning curves and drive predictable outcomes. Moreover, vendor credibility is reinforced by peer-reviewed clinical studies and real-world evidence that speak to safety and efficacy across anatomical applications.

Mergers, acquisitions, and licensing arrangements continue to shape the competitive landscape, with transactions often aimed at adding complementary technologies or expanding geographic reach. For decision-makers, the competitive implication is clear: success requires aligning product roadmaps with validated clinical protocols, investing in post-sales support, and building interoperable systems that integrate easily into diverse practice settings.

A pragmatic set of strategic initiatives that align product portfolios clinical evidence supply chain resilience and channel optimization to accelerate adoption and growth

Industry leaders should adopt a set of actionable initiatives to convert insight into market advantage and operational resilience. Prioritize portfolio strategies that balance flagship, multi-indication platforms with targeted applicators and protocols tailored to specific anatomical areas to meet clinician and patient needs. Simultaneously, invest in rigorous clinical studies and real-world data collection to substantiate claims, inform training curricula, and accelerate payer engagement where applicable.

Strengthen supply chain resilience by diversifying component sources, exploring regional assembly or nearshoring options, and building predictive inventory systems that reduce stockouts while minimizing capital tied up in spares. Commercially, refine channel strategies to support both high-touch direct sales for premium, service-intensive offerings and optimized online experiences for lower-complexity devices; within online ecosystems, prioritize robust content, virtual training modules, and digital marketplaces that facilitate discovery and post-purchase support.

Finally, align go-to-market initiatives with local regulatory and cultural nuances, deploying flexible pricing and financing options in markets with affordability constraints, and establishing partnerships with leading clinical influencers to accelerate adoption. These actions, when coordinated across product, clinical, supply chain, and commercial functions, will create durable competitive advantages.

A rigorous mixed-methods research approach combining clinician interviews device stakeholder input and comprehensive secondary analysis to validate practical industry insights

The research methodology blends primary stakeholder engagement with structured secondary analysis to ensure findings are grounded in contemporary practice and validated by multiple evidence streams. Primary engagement included in-depth interviews with clinicians across aesthetic clinics, dermatology practices, hospitals, and medispas to capture treatment selection rationales, procedural workflows, training needs, and post-procedure support expectations. These qualitative insights were triangulated with manufacturer and distributor interviews to understand product roadmaps, service models, and channel economics.

Secondary analysis encompassed regulatory documents, clinical trial registries, peer-reviewed literature, and industry-standard guidance to map safety profiles, usage indications, and evolving best practices. Careful attention was given to technology-specific performance characteristics across cryolipolysis, high intensity focused ultrasound, laser modalities including diode and Nd:YAG variants, and radiofrequency platforms in bipolar and monopolar configurations. Regional regulatory frameworks and distribution modalities were analyzed to surface practical considerations for market entry and ongoing compliance.

Data synthesis applied a cross-validation approach to reconcile differing perspectives and highlight robust trends. Limitations and assumptions are transparently documented, enabling readers to adapt insights to their unique strategic contexts and to commission targeted follow-on analyses where deeper granularity is required.

Concluding perspectives on how integrated product development clinical validation and adaptive commercialization will determine sustained success in the body contouring market

In closing, the body contouring sector is positioned at an inflection point where technology, consumer expectation, and clinical practice coalesce to create new avenues for patient-centered care and commercial innovation. The balance between invasive, minimally invasive, and non-invasive interventions will continue to shape provider offerings, while modality-specific strengths and complementary treatment combinations offer differentiated clinical value. Manufacturers and distributors that couple compelling device performance with robust clinical validation, comprehensive training, and resilient supply models will be best placed to win traction across diverse markets.

Regional nuances demand localized strategies that respect regulatory regimes, payment dynamics, and cultural attitudes toward aesthetics. The 2025 tariff environment further underscores the need for procurement agility and supply chain diversification. Ultimately, organizations that integrate evidence-driven product development with pragmatic commercial execution and a clear focus on clinician support will convert market complexity into sustainable advantage and improved patient outcomes.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Body Contouring Market, by Procedure Type

  • 8.1. Invasive
  • 8.2. Minimally Invasive
  • 8.3. Non Invasive

9. Body Contouring Market, by Technology

  • 9.1. Cryolipolysis
  • 9.2. High Intensity Focused Ultrasound
  • 9.3. Laser
    • 9.3.1. Diode
    • 9.3.2. Nd Yag
  • 9.4. Radiofrequency
    • 9.4.1. Bipolar
    • 9.4.2. Monopolar

10. Body Contouring Market, by End User

  • 10.1. Aesthetic Clinics
  • 10.2. Dermatology Clinics
  • 10.3. Hospitals
  • 10.4. Medispas

11. Body Contouring Market, by Application Area

  • 11.1. Abdomen
  • 11.2. Arm
  • 11.3. Back
  • 11.4. Thigh

12. Body Contouring Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Body Contouring Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Body Contouring Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Body Contouring Market

16. China Body Contouring Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. AbbVie Inc.
  • 17.6. Alma Lasers Ltd.
  • 17.7. Asclepion Laser Technologies GmbH
  • 17.8. Bausch Health Companies Inc.
  • 17.9. BioPhotas, Inc
  • 17.10. BTL Industries, Inc.
  • 17.11. Candela Corporation
  • 17.12. Cartessa Aesthetics
  • 17.13. Cutera, Inc.
  • 17.14. Cynosure LLC
  • 17.15. DEKA M.E.L.A. srl
  • 17.16. ENDYMED Medical
  • 17.17. Erchonia Corporation
  • 17.18. Fotona D.O.O.
  • 17.19. InMode Ltd.
  • 17.20. Lumenis Be Ltd.
  • 17.21. Merz Pharma GmbH & Co. KGaA
  • 17.22. MicroAire Surgical Instruments, LLC
  • 17.23. Nouvag AG
  • 17.24. Sciton Inc.
  • 17.25. Sofwave Ltd.
  • 17.26. Venus Concept Inc.
  • 17.27. Zimmer MedizinSystems

LIST OF FIGURES

  • FIGURE 1. GLOBAL BODY CONTOURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BODY CONTOURING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BODY CONTOURING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BODY CONTOURING MARKET SIZE, BY PROCEDURE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BODY CONTOURING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BODY CONTOURING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BODY CONTOURING MARKET SIZE, BY APPLICATION AREA, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BODY CONTOURING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BODY CONTOURING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BODY CONTOURING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES BODY CONTOURING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA BODY CONTOURING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BODY CONTOURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BODY CONTOURING MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BODY CONTOURING MARKET SIZE, BY INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BODY CONTOURING MARKET SIZE, BY INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BODY CONTOURING MARKET SIZE, BY INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BODY CONTOURING MARKET SIZE, BY MINIMALLY INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BODY CONTOURING MARKET SIZE, BY MINIMALLY INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BODY CONTOURING MARKET SIZE, BY MINIMALLY INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BODY CONTOURING MARKET SIZE, BY NON INVASIVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BODY CONTOURING MARKET SIZE, BY NON INVASIVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BODY CONTOURING MARKET SIZE, BY NON INVASIVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BODY CONTOURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BODY CONTOURING MARKET SIZE, BY CRYOLIPOLYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BODY CONTOURING MARKET SIZE, BY CRYOLIPOLYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BODY CONTOURING MARKET SIZE, BY CRYOLIPOLYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BODY CONTOURING MARKET SIZE, BY HIGH INTENSITY FOCUSED ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BODY CONTOURING MARKET SIZE, BY HIGH INTENSITY FOCUSED ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BODY CONTOURING MARKET SIZE, BY HIGH INTENSITY FOCUSED ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BODY CONTOURING MARKET SIZE, BY LASER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BODY CONTOURING MARKET SIZE, BY LASER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BODY CONTOURING MARKET SIZE, BY LASER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BODY CONTOURING MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BODY CONTOURING MARKET SIZE, BY DIODE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BODY CONTOURING MARKET SIZE, BY DIODE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BODY CONTOURING MARKET SIZE, BY DIODE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BODY CONTOURING MARKET SIZE, BY ND YAG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BODY CONTOURING MARKET SIZE, BY ND YAG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BODY CONTOURING MARKET SIZE, BY ND YAG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BODY CONTOURING MARKET SIZE, BY RADIOFREQUENCY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BODY CONTOURING MARKET SIZE, BY RADIOFREQUENCY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BODY CONTOURING MARKET SIZE, BY RADIOFREQUENCY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BODY CONTOURING MARKET SIZE, BY RADIOFREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BODY CONTOURING MARKET SIZE, BY BIPOLAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BODY CONTOURING MARKET SIZE, BY BIPOLAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BODY CONTOURING MARKET SIZE, BY BIPOLAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BODY CONTOURING MARKET SIZE, BY MONOPOLAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BODY CONTOURING MARKET SIZE, BY MONOPOLAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BODY CONTOURING MARKET SIZE, BY MONOPOLAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BODY CONTOURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BODY CONTOURING MARKET SIZE, BY AESTHETIC CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BODY CONTOURING MARKET SIZE, BY AESTHETIC CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BODY CONTOURING MARKET SIZE, BY AESTHETIC CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BODY CONTOURING MARKET SIZE, BY DERMATOLOGY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BODY CONTOURING MARKET SIZE, BY DERMATOLOGY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BODY CONTOURING MARKET SIZE, BY DERMATOLOGY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BODY CONTOURING MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BODY CONTOURING MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BODY CONTOURING MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BODY CONTOURING MARKET SIZE, BY MEDISPAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BODY CONTOURING MARKET SIZE, BY MEDISPAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BODY CONTOURING MARKET SIZE, BY MEDISPAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BODY CONTOURING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BODY CONTOURING MARKET SIZE, BY ABDOMEN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BODY CONTOURING MARKET SIZE, BY ABDOMEN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BODY CONTOURING MARKET SIZE, BY ABDOMEN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BODY CONTOURING MARKET SIZE, BY ARM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BODY CONTOURING MARKET SIZE, BY ARM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BODY CONTOURING MARKET SIZE, BY ARM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BODY CONTOURING MARKET SIZE, BY BACK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BODY CONTOURING MARKET SIZE, BY BACK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BODY CONTOURING MARKET SIZE, BY BACK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BODY CONTOURING MARKET SIZE, BY THIGH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BODY CONTOURING MARKET SIZE, BY THIGH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BODY CONTOURING MARKET SIZE, BY THIGH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BODY CONTOURING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS BODY CONTOURING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS BODY CONTOURING MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS BODY CONTOURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS BODY CONTOURING MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS BODY CONTOURING MARKET SIZE, BY RADIOFREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS BODY CONTOURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS BODY CONTOURING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA BODY CONTOURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA BODY CONTOURING MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA BODY CONTOURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA BODY CONTOURING MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA BODY CONTOURING MARKET SIZE, BY RADIOFREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA BODY CONTOURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA BODY CONTOURING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA BODY CONTOURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA BODY CONTOURING MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA BODY CONTOURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA BODY CONTOURING MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA BODY CONTOURING MARKET SIZE, BY RADIOFREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA BODY CONTOURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA BODY CONTOURING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA BODY CONTOURING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA BODY CONTOURING MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE, MIDDLE EAST & AFRICA BODY CONTOURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE, MIDDLE EAST & AFRICA BODY CONTOURING MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA BODY CONTOURING MARKET SIZE, BY RADIOFREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA BODY CONTOURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA BODY CONTOURING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE BODY CONTOURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE BODY CONTOURING MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE BODY CONTOURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE BODY CONTOURING MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE BODY CONTOURING MARKET SIZE, BY RADIOFREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE BODY CONTOURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE BODY CONTOURING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST BODY CONTOURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. MIDDLE EAST BODY CONTOURING MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. MIDDLE EAST BODY CONTOURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 104. MIDDLE EAST BODY CONTOURING MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 105. MIDDLE EAST BODY CONTOURING MARKET SIZE, BY RADIOFREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 106. MIDDLE EAST BODY CONTOURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST BODY CONTOURING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA BODY CONTOURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. AFRICA BODY CONTOURING MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. AFRICA BODY CONTOURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 111. AFRICA BODY CONTOURING MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 112. AFRICA BODY CONTOURING MARKET SIZE, BY RADIOFREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 113. AFRICA BODY CONTOURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 114. AFRICA BODY CONTOURING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC BODY CONTOURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. ASIA-PACIFIC BODY CONTOURING MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. ASIA-PACIFIC BODY CONTOURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. ASIA-PACIFIC BODY CONTOURING MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 119. ASIA-PACIFIC BODY CONTOURING MARKET SIZE, BY RADIOFREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 120. ASIA-PACIFIC BODY CONTOURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. ASIA-PACIFIC BODY CONTOURING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL BODY CONTOURING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN BODY CONTOURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASEAN BODY CONTOURING MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASEAN BODY CONTOURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. ASEAN BODY CONTOURING MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 127. ASEAN BODY CONTOURING MARKET SIZE, BY RADIOFREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 128. ASEAN BODY CONTOURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. ASEAN BODY CONTOURING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 130. GCC BODY CONTOURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 131. GCC BODY CONTOURING MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. GCC BODY CONTOURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 133. GCC BODY CONTOURING MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 134. GCC BODY CONTOURING MARKET SIZE, BY RADIOFREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 135. GCC BODY CONTOURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. GCC BODY CONTOURING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION BODY CONTOURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPEAN UNION BODY CONTOURING MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPEAN UNION BODY CONTOURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPEAN UNION BODY CONTOURING MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPEAN UNION BODY CONTOURING MARKET SIZE, BY RADIOFREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPEAN UNION BODY CONTOURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPEAN UNION BODY CONTOURING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS BODY CONTOURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. BRICS BODY CONTOURING MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. BRICS BODY CONTOURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. BRICS BODY CONTOURING MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 148. BRICS BODY CONTOURING MARKET SIZE, BY RADIOFREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 149. BRICS BODY CONTOURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. BRICS BODY CONTOURING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 151. G7 BODY CONTOURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 152. G7 BODY CONTOURING MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. G7 BODY CONTOURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 154. G7 BODY CONTOURING MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 155. G7 BODY CONTOURING MARKET SIZE, BY RADIOFREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 156. G7 BODY CONTOURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. G7 BODY CONTOURING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 158. NATO BODY CONTOURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 159. NATO BODY CONTOURING MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. NATO BODY CONTOURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 161. NATO BODY CONTOURING MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 162. NATO BODY CONTOURING MARKET SIZE, BY RADIOFREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 163. NATO BODY CONTOURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. NATO BODY CONTOURING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 165. GLOBAL BODY CONTOURING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES BODY CONTOURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 167. UNITED STATES BODY CONTOURING MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. UNITED STATES BODY CONTOURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 169. UNITED STATES BODY CONTOURING MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 170. UNITED STATES BODY CONTOURING MARKET SIZE, BY RADIOFREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 171. UNITED STATES BODY CONTOURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 172. UNITED STATES BODY CONTOURING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA BODY CONTOURING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 174. CHINA BODY CONTOURING MARKET SIZE, BY PROCEDURE TYPE, 2018-2032 (USD MILLION)
  • TABLE 175. CHINA BODY CONTOURING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 176. CHINA BODY CONTOURING MARKET SIZE, BY LASER, 2018-2032 (USD MILLION)
  • TABLE 177. CHINA BODY CONTOURING MARKET SIZE, BY RADIOFREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 178. CHINA BODY CONTOURING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 179. CHINA BODY CONTOURING MARKET SIZE, BY APPLICATION AREA, 2018-2032 (USD MILLION)